Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients.

@article{Schwentner2013ParticipationIA,
  title={Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients.},
  author={Lukas Schwentner and Reyn J G van Ewijk and Christian Kurzeder and Isabelle Hoffmann and Jochem K{\"o}nig and Rolf Kreienberg and Maria Blettner and Achim Woeckel},
  journal={European journal of cancer},
  year={2013},
  volume={49 3},
  pages={553-63}
}
UNLABELLED Adjuvant clinical trials (CTs) usually compare a standard treatment regime versus an innovative new substance or regimen. Participation in CT however, is available for only few patients and exclusion criteria are usually very strict. Therefore we used an unselected patient cohort to investigate the following questions: MATERIAL AND METHODS This German retrospective multi-centre cohort study included 9433 patients with primary breast cancer recruited from 1992 to 2008. RESULTS One… CONTINUE READING